The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | The role of Richter’s syndrome in determining the prognosis of CLL patients
Matthew Davids, MD, MMSc, from the Dana-Farber Cancer Institute, Boston, MA, discusses the importance of keeping patients with chronic lymphocytic leukemia (CLL) informed of when their Richter’s syndrome occurs, which can be predictive of their prognosis. He adds that his team’s goal in research is to develop better therapies for CLL patients with Richter’s syndrome. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
